Comparison of impurity profiles of Orlistat pharmaceutical products using HPLC tandem mass spectrometry

Journal of Pharmaceutical and Biomedical Analysis

Volumn 53, Issue 3, 2010, Pages 767-772

  Schneider, A ^a,b   Wessjohann, L A ^b  

^a IDrug GmbH   (Germany)

^b LEIBNIZ INSTITUTE OF PLANT BIOCHEMISTRY   (Germany)

Author keywords

Generic; HPLC MS MS; HPLC UV; Orlistat

Indexed keywords

ALCOHOL; COBESE; GENERIC DRUG; ORSOTEN; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG CAPSULE; DRUG FORMULATION; DRUG IMPURITY; DRUG ISOLATION; DRUG SOLUBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; OXIDATION; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ANTI-OBESITY AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CONTAMINATION; LACTONES; TANDEM MASS SPECTROMETRY;

EID: 77954860445     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.05.010     Document Type: Article

References (14)

1. Hadvary P., Hochuli E., Kupfer E., Lengsfeld H., Weibel E.K. Leucine derivatives. Eur. Pat. Appl. EP 1984, 0129748(A2).
2. Weibel E.K., Hadvary P., Hochuli E., Kupfer E., Lengsfeld H. Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. I. Producing organism, fermentation, isolation and biological activity. J. Antibiot. 1987, 40:1081-1085.
3. Hochuli E., Kupfer E., Mauer R., Meister W., Mercadal Y., Schmidt K. Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. II. Chemistry and structure elucidation. J. Antibiot. 1987, 40:1086-1091.
4. Karpf M., Zutter U. Production of oxetanones. Eur. Pat. Appl. EP 1991, 0443449(A2).
5. Broger E.A., Karpf M., Zutter U. Process for the preparation of optically active compounds. Eur. Pat. Appl. EP 1994, 0643052(A2).
6. Schwindt M.A., Fleming M.P., Han Y.K., Hodges L.M., Johnston D.A., Micheli R.P., Roberts C.R., Snyder R., Topping R.J., Puntener K., Scalone M. Enantioselective synthesis of a key intermediate in a new process for orlistat using asymmetric hydrogenation and a Grignard reagent promoted lactone cyclization. Org. Process Res. Dev. 2007, 11:524-533.
7. Bacher A., Stohler P. Process for the production of lipstatin and tetrahydrolipstatin. Eur. Pat. Appl. EP 1997, 0803576(A2).
8. Gomez Y., Adams E., Hoogmartens J. Analysis of purity in 19 drug product tablets containing clopidogrel: 18 copies versus the original brand. J. Pharm. Biomed. Anal. 2004, 34:341-348.
9. ®. J. Chemother. 2003, 15:357-368.
10. Mayeno A.N., Lin F., Foote C.S., Loegering D.A., Ames M.M., Hedberg C.W., Gleich G.J. Characterization of "peak E" , a novel amino acid associated with eosinophilia-myalgia syndrome. Science 1990, 250:1707-1708.
11. Wienen F, Deubner R., Holzgrabe U. Composition and impurity profile of multisource raw material of gentamicin-a comparison. Pharmeuropa 2003, 15:273-279.
12. Holzgrabe U., Deubner R., Wienen F. Quality of APIs-result of a research of different gentamicin products. Am. Pharm. Outsourc. 2004, 5:24-28.
13. Holzgrabe U. Verunreinigung von Arzneistoffen. Deutsche Apotheker Zeitung 2003, 143:3221-3228.
14. Stalder H., Schneider P.R., Oesterhelt G. 103. Tetrahydrolipstatin: thermal and hydrolytic degradation. Helv. Chim. Acta 1990, 73:1022-1036.